Ani Pharmaceuticals Inc. (ANIP)
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
ANI Pharmaceuticals rides Cortrophin Gel's surge to anchor 2026 growth, with rising guidance and new initiatives positioning the specialty portfolio for continued momentum.
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
ANI Pharmaceuticals trades at 10x forward earnings with a $93 target, but execution in Cortrophin and ophthalmology recovery may decide if the discount closes.
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
How Much Upside is Left in ANI (ANIP)? Wall Street Analysts Think 41.71%
The consensus price target hints at a 41.7% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ANI (ANIP) Upgraded to Strong Buy: Here's Why
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category.
3 Best Earnings Acceleration Stocks to Buy Now for April 2026
INTU, ANIP and GLPI stand out this April as earnings acceleration signals potential stock gains before broader market recognition kicks in.
